71569-15-8

Basic information

• Product Name: 5-AMINO-5,6,7,8-TETRAHYDROQUINOLINE
• Synonyms: 5-AMINO-5,6,7,8-TETRAHYDROQUINOLINE;5,6,7,8-TETRAHYDRO-QUINOLIN-5-YLAMINE;5,6,7,8-Tetrahydroquinolin-5-amine;5,6,7,8-tetrahydroquinolin-5-amine dihydrochloride;5,6,7,8-tetrahydro-5-quinolinamine(SALTDATA: 2HCl);5,6,7,8-tetrahydro-5-QuinolinaMine
• CAS NO: 71569-15-8
• Molecular Formula: C9H12N2
• Molecular Weight: 148.2
• Product Categories: pharmacetical
• Mol File: 71569-15-8.mol

Chemical Properties

• Boiling Point: 259.1 °C at 760 mmHg
• Flash Point: 134.3 °C
• Appearance: /
• Density: 1.081 g/cm³
• Vapor Pressure: 0.0132mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.57±0.20(Predicted)
• CAS DataBase Reference: 5-AMINO-5,6,7,8-TETRAHYDROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-5,6,7,8-TETRAHYDROQUINOLINE(71569-15-8)
• EPA Substance Registry System: 5-AMINO-5,6,7,8-TETRAHYDROQUINOLINE(71569-15-8)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 71569-15-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Amino-5,6,7,8-tetrahydroquinoline is used as a key intermediate in the synthesis of various pharmaceuticals due to its ability to participate in a wide range of chemical reactions. Its versatile structure makes it a valuable component in the development of new drugs.
Used in Medicinal Chemistry:
5-Amino-5,6,7,8-tetrahydroquinoline is used as a building block for the design and synthesis of bioactive compounds, contributing to the discovery of new therapeutic agents. Its potential for bioactive properties makes it an important compound in the field of medicinal chemistry.
Used in Drug Production:
5-Amino-5,6,7,8-tetrahydroquinoline is used as an intermediate in the production of more complex pharmaceuticals, playing a crucial role in the synthesis of drugs with diverse therapeutic applications. Its presence in the chemical structure of these drugs allows for the development of innovative treatments for various medical conditions.

InChI:InChI=1/C9H12N2/c10-8-4-1-5-9-7(8)3-2-6-11-9/h2-3,6,8H,1,4-5,10H2

Upstream product

• 1114896-36-4 (Z/E)-7,8-dihydroquinolin-5(6H)-one O-methyl oxime 
• 185510-52-5 5-(N-acetylamino)-5,6,7,8-tetrahydroquinoline 
• 298182-09-9 N-(5,6,7,8-tetrahydroquinolin-7-yl)acetamide 
• 53400-41-2 5,6,7,8-tetrahydroquinolin-5-one 

Downstream Products

• 911825-73-5 (S)-5,6,7,8-tetrahydroquinolin-5-ylamine 

Relevant articles and documents

CXCR2 ANTAGONIST

A compound as a CXCR2 antagonist and an application thereof in preparing a drug as a CXCR2 antagonist. In particular, the present invention relates to a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof.

ADRENERGIC COMPOUNDS

Disclosed herein is an alpha - adrenergic compound having a structure. Therapeutic methods, compositions, and medicaments for treating pain are also disclosed herein.

Chemokine receptor binding heterocyclic compounds

This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y═H; R1to R7may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C1-6alkyl; R8is a substituted heterocyclic group or a substituted aromatic group Ar is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and n′ are independently, 0-2; X is a group of the formula: Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond, a (CH2)n″group (where n″=0-2) or a C═O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C1-6alkyl group, (3) a C0-6alkyl group substituted with an optionally substituted aromatic or heterocyclic group, (4) an optionally substituted C0-6alkylamino or C3-7cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salts and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

Pyrrolidine-modified and 6-substituted analogs of nicotine: a structure-affinity investigation

Because the structural requirements for the binding of nicotine to central nicotine receptors remain largely uninvestigated, we undertook a systematic investigation of pyrrolidine ring-opened analogs.This led to a subsequent investigation of related conformationally restricted derivatives of these analogs.The results are reported relative to the binding of several well-known and widely used nicotine receptor ligands.Although none of the ring-opened analogs binds with higher affinity than (-)-nicotine (Ki = 2.3 nM), 3-(N-methyl-N-ethylaminomethyl)pyridine (12a; Ki = 28 nM) binds with significant affinity.A conformationally restricted analog of 12a, N-methyl naphthyridine 30b (Ki = 18 nM), binds with similar affinity. 6-Substitution of 12a and racemic nicotine seems to be tolerated when the substituent is halogen or methyl.In functional studies (hypolocomotion and antinociception in mice; stimulus generalization in nicotine-trained rats) 30b retains nicotine-like properties.Several of the 6-substituted compounds were 2 to 20 times more potent than (+/-)nicotine.Although the intact pyrrolidine ring of nicotine appears important for optimal affinity, its presence is not an absolute requirement for activity, and 6-position substitution of the pyridine nucleus can influence both binding and functional activity. - Keywords: nicotine; nicotine receptor; drug discrimination; antinociception.